Homepage
Author:
Cerevance, Inc.
Posted Date:
May 12, 2026
Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027
Cerevance, Inc.
May 12, 2026
Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting
Cerevance, Inc.
April 9, 2026
Cerevance to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cerevance, Inc.
April 8, 2026
Cerevance to Present Phase 2 Trial Results on OFF Time and Sleep‑Related Outcomes with Solengepras in Parkinson’s Disease at AD/PD™ 2026
Cerevance, Inc.
March 10, 2026
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
Cerevance, Inc.
February 23, 2026
